In this issue of JAMA, the US Preventive Services Task Force (USPSTF) releases its recommendations on lipid screening in children and adolescents,1 updating the 2007 recommendation on this topic.2 The 2016 recommendation statement is accompanied by 2 companion Evidence Reports on screening for detection of familial hypercholesterolemia (FH)3 and multifactorial dyslipidemia.4 The conclusion of the task force is unchanged from 2007: “The current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents younger than 20 years.”1 The purpose of this Editorial is to provide additional context for clinicians, policy makers, patients, and their families deciphering the meaning and implications of the “I” statement as they engage in their own informed health care decision making.
Urbina EM, de Ferranti SD. Lipid Screening in Children and Adolescents. JAMA. 2016;316(6):589-591. doi:10.1001/jama.2016.9671